---
title: 'Funding Daily Summary: What Happened on November 4, 2026'
headline: Warp Sciences raises $215 million to build a US chemistry business
description: Caspian raised $50 million for a diabetes drug. Two UK biotech companies
  received £500,000 each.
url: https://thebench.bio/news/funding/2026-11-04
topic: funding
date: '2026-11-04'
covers:
- '2026-11-04'
date_published: '2026-11-04T12:01:56Z'
date_modified: '2026-11-04T12:01:56Z'
tags:
- Industry
- Software
sources: 3
publisher: TheBench.Bio
---

# Funding Daily Summary: What Happened on November 4, 2026

**Warp Sciences raises $215 million to build a US chemistry business**

Caspian raised $50 million for a diabetes drug. Two UK biotech companies received £500,000 each.

## Today in brief

Warp Sciences emerged from stealth with $215 million to build a US contract research business for medicinal chemistry, using chemists, AI and robots. [1] The financing values the company at $865 million. [1]

Caspian raised $50 million to develop an oral drug intended to regenerate insulin-producing pancreatic beta cells. [2] Medicines Discovery Catapult awarded £500,000 each to Flip Therapeutics and Nascent Therapeutics. [3]

## Warp Sciences raises $215 million for a US chemistry operation

Warp Sciences emerged from stealth with $215 million in financing led by Lightspeed, at an $865 million valuation. [1] The company plans a US contract research operation for medicinal chemistry that combines experienced chemists, AI and robots. [1]

Warp says it will charge for each compound delivered, rather than for chemist time. [1] The process starts with chemists, whose work provides data to automate more of the chemistry over time. [1]

Whether robots can stay busy, handle complex chemistry and compete with overseas providers on price remains an open question. [1]

## Caspian raises $50 million for a beta-cell-regenerating drug

Caspian, a Kura Oncology spinout, raised $50 million to develop KO-7246, an oral menin inhibitor intended to regenerate pancreatic beta cells. [2]

Executive chairman and co-founder Troy Wilson said Caspian plans to test the drug in healthy volunteers in 2027, then in people with diabetes in 2028. [2]

## Also worth knowing

- Medicines Discovery Catapult awarded £500,000 each to Flip Therapeutics, developing T-cell treatments for alopecia and psoriasis, and Nascent Therapeutics, which applies mitochondrial biology to diseases including cancer and neurodegeneration. [3]

## The day in numbers

- **$215 million**: Warp Sciences' financing to build a US medicinal-chemistry contract research business. [1]
- **$865 million**: Warp Sciences' valuation in the financing. [1]
- **$50 million**: Caspian's funding for development of KO-7246. [2]
- **£500,000 each**: Funding awarded to Flip Therapeutics and Nascent Therapeutics. [3]

## Sources

1. [Weekly Tech+Bio #89: Can Robots Bring Drug-Discovery Chemistry Back to the US?](<https://www.techlifesci.com/p/weekly-techbio-89-can-robots-bring>), Weekly Tech+Bio, 2026-11-04
2. [Caspian: Regenerating beta cells with a menin inhibitor](<https://www.biocentury.com/article/661389/caspian-regenerating-beta-cells-with-a-menin-inhibitor?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-04
3. [How chronic disease creates opportunity on diagnostic and therapeutic pipelines](<https://pharmafile.com/features/how-chronic-disease-creates-opportunity-on-diagnostic-and-therapeutic-pipelines/>), Pharmafile, 2026-11-04

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.techlifesci.com/p/weekly-techbio-89-can-robots-bring>
[2]: <https://www.biocentury.com/article/661389/caspian-regenerating-beta-cells-with-a-menin-inhibitor?utm_source=bc_rss&utm_medium=rss>
[3]: <https://pharmafile.com/features/how-chronic-disease-creates-opportunity-on-diagnostic-and-therapeutic-pipelines/>